Table 19:
Results of Budget Impact Analysis of Publicly Funding the Prolaris Cell Cycle Progression Test for Low- and Intermediate-Risk Localized Prostate Cancer
| Net Budget Impact, $ Million | ||||||
|---|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | 5-Year Total | |
| Additional cost associated with the CCP test | 4.1 | 6.8 | 9.6 | 12.3 | 15.1 | 47.9 |
| Additional cost associated with extra physician visits | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.7 |
| Cost offset associated with treatment changes | −0.5 | −0.9 | −1.4 | −2.0 | −2.6 | −7.3 |
| Total costs | 3.7 | 6.1 | 8.3 | 10.5 | 12.7 | 41.3 |
Abbreviation: CCP, Prolaris cell cycle progression.